Reverse Vaccinology Approach to Potential Vaccine Candidates Against Acinetobacter baumannii
- PMID: 30798567
- DOI: 10.1007/978-1-4939-9118-1_29
Reverse Vaccinology Approach to Potential Vaccine Candidates Against Acinetobacter baumannii
Abstract
Acinetobacter baumannii is a rapidly evolving pathogen that largely inhabits intensive care units (ICU). This opportunistic, gram-negative organism has shown noteworthy taxonomic variations during the past three decades. A. baumannii functions as a catalase-positive, oxidase-negative obligate, aerobic, nonmotile, highly infectious, and multidrug-resistant bacterium. Therefore, the infection caused by this bacterium tends to have a fairly higher incidence rate in immune-compromised individuals ranging from 26.5% to 91%, as it colonizes in skin tissues and secretions of the respiratory tract. Recently, it has been globally labeled as a "red alert" pathogen, setting alarms throughout the medical community, arising mainly due to its widespread antibiotic resistance continuum. There is a dire need for alternative therapeutic intervention to combat A. baumannii-associated infections and the growing resistance. This chapter focuses upon the reverse vaccinology-based steps and strategies to identify novel potential vaccine candidates against this emerging pathogen.
Keywords: A. baumannii; Antibiotic resistance; In silico; PVCs; Reverse vaccinology.
Similar articles
-
Antibiotic Resistance Determinant-Focused Acinetobacter baumannii Vaccine Designed Using Reverse Vaccinology.Int J Mol Sci. 2017 Feb 21;18(2):458. doi: 10.3390/ijms18020458. Int J Mol Sci. 2017. PMID: 28230771 Free PMC article.
-
Delineating the Plausible Molecular Vaccine Candidates and Drug Targets of Multidrug-Resistant Acinetobacter baumannii.Front Cell Infect Microbiol. 2019 Jun 20;9:203. doi: 10.3389/fcimb.2019.00203. eCollection 2019. Front Cell Infect Microbiol. 2019. PMID: 31281799 Free PMC article.
-
Chimeric vaccine designs against Acinetobacter baumannii using pan genome and reverse vaccinology approaches.Sci Rep. 2021 Jun 24;11(1):13213. doi: 10.1038/s41598-021-92501-8. Sci Rep. 2021. PMID: 34168196 Free PMC article.
-
Acinetobacter baumannii subunit vaccines: recent progress and challenges.Crit Rev Microbiol. 2024 Aug;50(4):434-449. doi: 10.1080/1040841X.2023.2215303. Epub 2023 May 21. Crit Rev Microbiol. 2024. PMID: 37211625 Review.
-
First steps towards a vaccine against Acinetobacter baumannii.Curr Pharm Biotechnol. 2013;14(10):897-902. doi: 10.2174/1389201014666131226123511. Curr Pharm Biotechnol. 2013. PMID: 24372252 Review.
Cited by
-
Non-antibiotic prevention and treatment against Acinetobacter baumannii infection: Are vaccines and adjuvants effective strategies?Front Microbiol. 2023 Jan 25;14:1049917. doi: 10.3389/fmicb.2023.1049917. eCollection 2023. Front Microbiol. 2023. PMID: 36760499 Free PMC article. Review.
-
DNA vaccine encoding OmpA and Pal from Acinetobacter baumannii efficiently protects mice against pulmonary infection.Mol Biol Rep. 2019 Oct;46(5):5397-5408. doi: 10.1007/s11033-019-04994-2. Epub 2019 Jul 24. Mol Biol Rep. 2019. PMID: 31342294
-
Immune Response to Conjugates of Fragments of the Type K9 Capsular Polysaccharide of Acinetobacter baumannii with Carrier Proteins.Microbiol Spectr. 2022 Oct 26;10(5):e0167422. doi: 10.1128/spectrum.01674-22. Epub 2022 Aug 18. Microbiol Spectr. 2022. PMID: 35980044 Free PMC article.
-
Designing Multi-Antigen Vaccines Against Acinetobacter baumannii Using Systemic Approaches.Front Immunol. 2021 Apr 16;12:666742. doi: 10.3389/fimmu.2021.666742. eCollection 2021. Front Immunol. 2021. PMID: 33936107 Free PMC article.
-
Immunogenicity of trimeric autotransporter adhesins and their potential as vaccine targets.Med Microbiol Immunol. 2020 Jun;209(3):243-263. doi: 10.1007/s00430-019-00649-y. Epub 2019 Dec 1. Med Microbiol Immunol. 2020. PMID: 31788746 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous